Notably, treatment of Icam1-/- mice with anti-VCAM-1 reduced leukemic burden significantly more than single Icam1 deficiency or anti-VCAM-1 treatment (Fig. 3h), indicating that both ICAM-1 and VCAM-1 contribute to T-ALL progression. This evidence concerns the gene VCAM1 and acute lymphoblastic leukemia.